Learn more about our technologies, company and capabilities
WuXi Biologics Completed Three Acquisitions to
Enhance its Global Network
Read More
WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services
Read More
WuXi Biologics Receives GMP Conformity Assessment from the Singapore Health Sciences Authority (HSA)
Read More
WuXi Biologics Successfully Completed Pre-License Inspection and Routine GMP Inspection by U.S. FDA
Read More
WuXi Biologics Receives GMP Certification from Brazil’s ANVISA
Read Mor
e
The World's Largest 36,000L Biomanufacturing Line Using Single-use Bioreactors Launches GMP Operation at WuXi Biologics
Read More
Our Regulatory Affairs team provides a quarterly summary of updates organized by agency and by topic. These updates support your efforts to stay current in our ever-changing regulatory environment.
For more information - See this Podcast
We're Hiring in the USA, Germany, Ireland, China and More -
Join Us
!
WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates
Read More
WuXi Biologics Congratulates Emergency Use Authorization of Sotrovimab for the treatment of COVID-19
Read More
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
Read More
WuXi Biologics Congratulates Vir Biotechnology on Positive Data from Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection
Read More
WuXi Biologics, WuXi STA and Antengene Announce Collaboration to Advance Antibody-Drug Conjugate Candidate into Clinical Stage
Read More
Antibody Drug Conjugates (ADC) Drug Development and Manufacturing Trends, Challenges and Solutions
(Webinar)
_______________________________
Expediting Biologics Drug Development: Strategies to Accelerate Preclinical Development Timelines
(Webinar)
_______________________________
Applications and Impact of CRISPR/Cas9 in Bioprocessing
(Podcast)
_____________________________
Continuous Biomanufacturing Implementation – Using an Intensified and Integrated Bioprocess Platform
(White Paper)
_______________________________
Reducing Fill Risk in Drug Product Manufacture Utilizing New State-of-the-Art Systems and Platforms
(Podcast)
_______________________________
Scale-Out Biomanufacturing – A Paradigm Change to Scale-Up
(White Paper)
WuXi Biologics Named China's Most Attractive Employer
Read More
To read more about WuXi Biologics visit our
Newsletter Archive
Follow Us!